Annual Report 2023

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2023 151 The United Laboratories International Holdings Limited Annual Report 2023 Name of subsidiaries Place of incorporation/ establishment Issued and fully paid share capital/ registered capital Attributable equity interest held by the Company Principal activities and place of operation (Note a) 2023 2022 珠海聯邦生物醫藥有限公司 (Note c) The PRC RMB100,000,000 100% 100% Research and development of pharmaceutical products in the PRC Henan Lianmu Veterinary Medicine Co., Ltd. (Note c) The PRC RMB35,000,000 60% 60% Manufacturing and sale of veterinary drugs in the PRC Kendor Technology (Zhejiang) Co., Ltd. (Note b) The PRC RMB15,500,000 100% 100% Manufacturing and sale of medical device in the PRC 珠海聯邦動保有限公司 (Note e) The PRC RMB18,000,000 100% N/A Manufacturing and sale of veterinary drugs in the PRC Notes: (a) Other than The United Laboratories (Hong Kong) Holding Limited, all subsidiaries are indirectly held by the Company. (b) A wholly foreign-owned enterprise established in the PRC. (c) A company established in the PRC with limited liability. (d) A joint stock limited liability company established in the PRC. (e) A wholly foreign-owned company established in the PRC with limited liability during the year ended 31 December 2023. 45. PARTICULARS OF PRINCIPAL SUBSIDIARIES OF THE COMPANY (Continued)